Objective:This research is to investigate the antihyperglycaemic activity and the underlying mechanisms of action of the ethylacetate extract of Chlorophytum alismifolium(EACA)tubers in a type 2 diabetes model.Methods...Objective:This research is to investigate the antihyperglycaemic activity and the underlying mechanisms of action of the ethylacetate extract of Chlorophytum alismifolium(EACA)tubers in a type 2 diabetes model.Methods:The tubers were processed and sequentially extracted in hexane followed by ethylacetate,using a Soxhlet apparatus,and subjected to gas chromatography-mass spectrometry(GC–MS).The acute toxicity of EACA was investigated in albino Wistar rats.An antihyperglycaemic study was carried out using high-fat diet(pelletized diet and margarine in the ratio of 10:1 and 20%fructose solution)and streptozotocin-induced hyperglycaemic Wistar rats.The effects of the extract(150,300 and 600 mg/kg)on blood glucose level,insulin,peroxisome proliferator-activated receptor-c(PPAR-c)and dipeptidyl peptidase-4(DPP-4)were evaluated using enzyme-linked immunosorbent assay.Results:The oral median lethal dose in Wistar rats was estimated to be>5000 mg/kg.Treatment with EACA at all doses significantly reduced the fasting blood glucose levels,compared to the hyperglycaemic control,and over time.Administration of EACA increased the serum insulin and PPAR-c levels while decreasing DPP-4 levels.GC–MS analysis revealed the presence of 13 compounds,with isothiazole and isoxazolidine covering total area of 24.6%and 22.69%,respectively.Conclusion:The findings from this study showed that EACA has important compounds with beneficial effect in type 2 diabetes and acts by increasing insulin secretion and PPAR-c level and decreasing DPP-4 activity.展开更多
文摘Objective:This research is to investigate the antihyperglycaemic activity and the underlying mechanisms of action of the ethylacetate extract of Chlorophytum alismifolium(EACA)tubers in a type 2 diabetes model.Methods:The tubers were processed and sequentially extracted in hexane followed by ethylacetate,using a Soxhlet apparatus,and subjected to gas chromatography-mass spectrometry(GC–MS).The acute toxicity of EACA was investigated in albino Wistar rats.An antihyperglycaemic study was carried out using high-fat diet(pelletized diet and margarine in the ratio of 10:1 and 20%fructose solution)and streptozotocin-induced hyperglycaemic Wistar rats.The effects of the extract(150,300 and 600 mg/kg)on blood glucose level,insulin,peroxisome proliferator-activated receptor-c(PPAR-c)and dipeptidyl peptidase-4(DPP-4)were evaluated using enzyme-linked immunosorbent assay.Results:The oral median lethal dose in Wistar rats was estimated to be>5000 mg/kg.Treatment with EACA at all doses significantly reduced the fasting blood glucose levels,compared to the hyperglycaemic control,and over time.Administration of EACA increased the serum insulin and PPAR-c levels while decreasing DPP-4 levels.GC–MS analysis revealed the presence of 13 compounds,with isothiazole and isoxazolidine covering total area of 24.6%and 22.69%,respectively.Conclusion:The findings from this study showed that EACA has important compounds with beneficial effect in type 2 diabetes and acts by increasing insulin secretion and PPAR-c level and decreasing DPP-4 activity.
